Paul Wallace joined Mission Therapeutics in 2015 as Chief Business Officer.

Dr Wallace brings 25 years of international business development experience, having worked across this role with several private and publicly listed companies. Most recently, he was EVP and Head of Business Development for Medivir AB during its transition from an early-stage R&D company into a profitable pharmaceutical company with commercial sales. He has been involved in several trade sales and has led the execution of multiple partnership transactions with major pharmaceutical companies, resulting in the launch of two drugs, including the hepatitis C protease inhibitor, Olysio®. Prior to his roles in business development, Dr Wallace had a career in pharmaceutical research developing antibody therapeutics for oncology indications. He carried out his PhD and post-doctoral studies in biochemistry at the University of Cambridge and has a BSc in biochemistry from the University of St Andrews, Scotland.